885223-63-2

Basic information

• Product Name: 5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide
• Synonyms: 5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide;N-Methoxy-N-methyl 5-bromo-2-chloronicotinamide;5-broMo-2-chloro-N-Methoxy-N-MethylnicotinaMide
• CAS NO: 885223-63-2
• Molecular Formula: C8H8BrClN2O2
• Molecular Weight: 279.51832
• Mol File: 885223-63-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide(885223-63-2)
• EPA Substance Registry System: 5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide(885223-63-2)

Safety Data

• Hazardous Substances Data: 885223-63-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide is utilized as a reagent in organic synthesis for its ability to participate in a variety of chemical reactions, facilitating the creation of new compounds with potential applications across different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Bromo-2-chloro-N-methoxy-N-methylpyridine-3-carboxamide is employed as a key intermediate. Its role is crucial in the development and preparation of various pharmaceuticals, where its unique structure and functional groups can be leveraged to design and synthesize new drugs with specific therapeutic properties.
Given the provided materials, there are no specific applications detailed beyond its use as a reagent in organic synthesis and as an intermediate in pharmaceutical research. However, the compound's potential biological activity suggests that it may also be explored for direct therapeutic uses in medicine, pending further research and development.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 29241-65-4 5-bromo-2-chloronicotinic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 228251-24-9 5-bromo-2-chloropyridine-3-carbaldehyde 
• 1552301-52-6 N-(5-(2-amino-4-methylpyrido[2,3-d]pyrimidin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 886365-47-5 1-(5-bromo-2-chloropyridin-3-yl)ethanone 
• 1401731-54-1 MR⁽⁰³³⁾T₀₀₆₅₉ 
• 928653-74-1 5-bromo-2-chloro-3-(dimethoxymethyl)pyridine 

Relevant articles and documents

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

CERTAIN PROTEIN KINASE INHIBITORS

Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors

Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naph

Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives

Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway by PI3K/mTOR dual inhibitors provides a promising new approach to the treatment of cancers. In this Letter, we identified structurally novel and

A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway

Reactivation of the wild-type p53 pathway is one key goal aimed at developing targeted therapeutics in the cancer research field. Although most p53 protein kinases form 'p53-activating' signals, there are few kinases whose action can contribute to the inhibition of p53, as Casein kinase 1 (CK1) and Checkpoint kinase 1 (CHK1). Here we report on a pyrazolo-pyridine analogue showing activity against both CK1 and CHK1 kinases that lead to p53 pathway stabilisation, thus having pharmacological similarities to the p53-activator Nutlin-3. These data demonstrate the emerging potential utility of multivalent kinase inhibitors.

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

THIADIAZOLE COMPOUNDS AND METHODS OF USE

The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated